Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? - Results of a study in 50 patients

Urology

Volumn 54, Issue 5, 1999, Pages 900-904

  Cremerius, Uwe ^a   Wildberger, Joachim E ^a   Borchers, Holger ^a   Zimny, Michael ^a   Jakse, Gerhard ^a   Günther, Rolf W ^a   Buell, Udalrich ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; FLUORODEOXYGLUCOSE F 18; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; PARAAORTIC LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; TESTIS CANCER;

ADULT; AGED; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GERM CELL AND EMBRYONAL; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; TESTICULAR NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0032699376     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00272-1     Document Type: Article

References (23)

1. Gatti J.M., Stephenson R.A. Staging of testis cancer. Combining serum markers, histologic parameters, and radiographic imaging. Urol Clin North Am. 25:1998;397-403.
2. Fernandez E.B., Moul J.W., Foley J.P., et al. Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumors. Urology. 44:1994;548-552.
3. Donohue J.P., Foster R.S. Retroperitoneal lymphadenectomy in staging and treatment. The development of nerve-sparing techniques. Urol Clin North Am. 25:1998;461-468.
4. Warburg O: The Metabolism of Tumours. London, England, Constable, 1930.
5. Hoh C.K., Seltzer M.A., Franklin J., et al. Positron emission tomography in urological oncology. J Urol. 159:1998;347-356.
6. Schiepers C., Hoh C.K. Positron emission tomography as a diagnostic tool in oncology. Eur Radiol. 8:1998;1481-1494.
7. Sobin LH, and Wittekind C (Eds): TNM Classification of Malignant Tumours, 5th ed. New York, John Wiley & Sons, 1997, pp 174-179.
8. Vinnicomb S.J., Norman A.R., Nicolson V., et al. Normal pelvic lymph nodes evaluation with CT after bipedal lymphangiography . Radiology. 194:1995;349-355.
9. Cremerius U., Effert P.J., Adam G., et al. FDG PET for detection and therapy control of metastatic germ cell tumor. J Nucl Med. 39:1998;815-822.
10. Strauss L.G., Conti P.S. The applications of PET in clinical oncology. J Nucl Med. 32:1991;623-648.
11. Wilson C.B., Young H.E., Ott R.J., et al. Imaging metastatic germ cell tumours with 18FDG positron emission tomography prospects for detection and management . Eur J Nucl Med. 22:1995;508-513.
12. Stephens A.W., Gonin R., Hutchins G.D., et al. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol. 14:1996;1637-1641.
13. Nuutinen J.M., Leskinen S., Elomaa I., et al. Detection of residual tumours in postchemotherapy testicular cancer by FDG-PET. Eur J Cancer. 33:1997;1234-1241.
14. Bender H., Schomburg A., Albers P., et al. Possible role of FDG-PET in the evaluation of urologic malignancies. Anticancer Res. 17:1997;1655-1660.
15. Müller-Mattheis V., Reinhardt M., Gerharz C.D., et al. Positron emission tomography with 18F-2-fluoro-2-deoxy-D-glucose (18-FDG-PET) in the diagnosis of retroperitoneal lymph-node metastases from testicular tumors. Urologe A. 37:1998;609-620.
16. Heidenreich A., Sesterhenn I.A., Mostofi F.K., et al. Prognostic risk factors identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. Cancer. 83:1998;1002-1011.
17. Leibovitch I., Foster R.S., Kopecky K.K., et al. Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease a combined approach using quantitative immunohistochemical, histopathologic, and radiological assessment . J Clin Oncol. 16:1998;261-268.
18. Rayson D., Burch P.A., Richardson R.L. Sarcoidosis and testicular cancer. Cancer. 83:1998;337-343.
19. Brudin L.H., Valind S.O., Rhodes C.G., et al. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med. 21:1994;297-305.
20. Hoffmann E.J., Huang S.C., Phelps M.E. Quantitation in positron emission computed tomography 1. Effect of object size . J Comput Assist Tomogr. 3:1979;299-308.
21. Raylman R.R., Kison P.V., Wahl R.L. Capabilities of two- and three-dimensional FDG-PET for detecting small lesions and lymph nodes in the upper torso a dynamic PET study . Eur J Nucl Med. 26:1999;39-45.
22. Hilton S., Herr H.W., Teitcher J.B. CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer assessment of size and distribution criteria . AJR Am J Roentgenol. 169:1997;521-525.
23. De Wit M, Bares R, and Heicappell R: Untersuchung zur Bedeutung der Positronen-Emissions-Tomographie (PET) im Therapiemanagement von Keimzelltumoren. Available at: http://www.medizin.fu-berlin.de/AUO. Accessed May 1, 1999.